Dyslipidaemia and cardiovascular risk in HIV infection

Current Medical Research and Opinion

Volumn 21, Issue 11, 2005, Pages 1717-1725

  Kulasegaram, Ranjababu ^a   Peters, Barry S ^a,b   Wierzbicki, Anthony S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

AIDS; Atherosclerosis; HIV; Lipid; Lipodystrophy

Indexed keywords

ANTIVIRUS AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LIPID; NELFINAVIR; NICOTINIC ACID; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; SAQUINAVIR; STAVUDINE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DATA BASE; DISEASE COURSE; DRUG EFFECT; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPODYSTROPHY; MITOCHONDRIAL TOXICITY; PATHOGENESIS; REVIEW; TOXICITY;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; LIPIDS; RISK FACTORS;

EID: 27944471711     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X65529     Document Type: Review

References (100)

1. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. New Engl J Med 2003;348(8):702-10
2. Kuritzkes DR, Currier J. Cardiovascular risk factors and antiretroviral therapy. New Engl J Med 2003;348(8):679-80
3. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease - is there a link? Lancet 1997;350(9):430-6
4. Constans J, Seigneur M, Blann A, et al. Chronic infections and coronary heart disease. Lancet 1997;350(9083):1030
5. Boring L, Gosling J, Cleary M, et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394(6696):894-7
6. Louie JK, Hsu LC, Osmond DH, et al. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis 2002;186(7):1023-7
7. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24(6):416-20
8. Constans J, Marchand JM, Conri C, et al. Asymptomatic atherosclerosis in HIV-positive patients: a case-control ultrasound study. Ann Med 1995;27(6):683-5
9. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328
10. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(7):F51-F58
11. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32(1):130-9
12. Kereveur A, Cambillau M, Kazatchkine M, et al. Lipoprotein anomalies in HIV infections. Ann Med Interne (Paris) 1996;147(5):333-43
13. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999;100(7):700-5
14. Roberts AD, Muesing RA, Parenti DM, et al. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis 1999;29(2):441-3
15. Ducobu J, Payen MC. Lipids and AIDS. Rev Med Brux 2000;21(1):11-7
16. Qaqish RB, Fisher E, Rublein J, et al. HIV-associated lipodystrophy syndrome. Pharmacotherapy 2000;20(1):11-7
17. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003;361(9359):726-35
18. Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003;33(5):571-6
19. Carter VM, Hoy JF, Bailey M, et al. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med 2001;2(3):174-80
20. Ioannidis JP, Trikalinos TA, Law M, et al. HIV lipodystrophy case definition using artificial neural network modelling. Antivir Ther 2003;8(5):435-41
21. Sadowinski-Pine S, Cabrera-Munoz ML, Valencia-Mayoral P, et al. Coronary arteriopathy associated with cardiomyopathy in an adolescent with AIDS. Bol Med Hosp Infant Mex 1992;49(9):605-9
22. Park YD, Belman AL, Kim TS, et al. Stroke in pediatric acquired immunodeficiency syndrome. Ann Neurol 1990;28(3):303-11
23. Moriarty DM, Haller JO, Loh JP, et al. Cerebral infarction in pediatric acquired immunodeficiency syndrome. Pediatr Radiol 1994;24(8):611-2
24. Paton P, Tabib A, Loire R, et al. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993;144(3):225-31
25. Siscovick DS, Schwartz SM, Corey L, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: the Cardiovascular Health Study. Circulation 2000;102(19):2335-40
26. Laurence J. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1960
27. Anderson DW, Virmiani R. Emerging patterns of heart disease in HIV infection. Hum Pathol 1990;21:253-9
28. Patel RC, Frishman WH. Cardiac involvement in HIV infection. Med Clin (North Am) 1997;80:1493-512
29. Mercie P, Thiebaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002;34(1):55-63
30. Seminari E, Pan A, Voltini G, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002;162(2):433-8
31. Ginsberg HN, Stalenhoef AF. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. J Cardiovasc Risk 2003;10(2):121-8
32. Meng Q, Lima JA, Lai H, et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 2002;144(4):642-8
33. Lai S, Lima JA, Lai H, et al. Human immunodeficiency virus 1 infection, cocaine, and coronary calcification. Arch Intern Med 2005;165(6):690-5
34. Bharati S, Joshi VV, Connor EM. Conduction syndrome in children with AIDS. Chest 1989;96:406-13
35. Koppel K, Bratt G, Schulman S, et al. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29(5):441-9
36. Eldor A. Thrombotic thrombocytopenic purpura: diagnosis, pathogenesis and modern therapy. Bailliere's Clin Haematol 1998;11(2):475-95
37. Laurence J, Mitra D, Steiner M, et al. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood 1996;87(8):3245-54
38. Chi D, Henry J, Kelley J, et al. The effects of HIV infection on endothelial function. Endothelium 2000;7(4):223-42
39. Adamson DC, Dawson TM, Zink MC, et al. Neurovirulent simian immunodeficiency virus infection induces neuronal, endothelial, and glial apoptosis. Mol Med 1996;2(4):417-28
40. Huang MB, Khan M, Garcia-Barrio M, et al. Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120. J Acquir Immune Defic Syndr 2001;27(3):213-21
41. Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. Prog Cardiovasc Dis 2000;43(2):151-70
42. Sani MU, Okeahialam BN, Aliyu SH, et al. Human immunodeficiency virus (HIV) related heart disease: a review. Wien Klin Wochenschr 2005;117(3):73-81
43. Lewis W. AIDS Cardiomyopathy: physiological, molecular, and biochemical studies in the transgenic mouse. Ann NY Acad Sci 2001;946:46-56
44. Twu C, Liu NQ, Popik W, et al. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. Proc Natl Acad Sci USA 2002;99(22):14386-91
45. Lewis W. Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS Cardiomyopathy. Prog Cardiovasc Dis 2003;45(4):305-18
46. Thiebaut R, Dabis F, Malvy D, et al. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996-1998 [Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA)]. J Acquir Immune Defic Syndr 2000;23(3):261-5
47. Weinroth SE, Parenti DM, Simon GL. Wasting syndrome in AIDS; pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis 1995;4:76-94
48. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991;90(2):154-62
49. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74(5):1045-52
50. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and acquired immune deficiency syndrome. Endocrin Rev 1996;17:518-32
51. Pirich C, Efthimiou Y, O'Grady J, et al. Apolipoprotein A and biological half-life of prostaglandin 12 in HIV-1 infection. Thromb Res 1996;81(2):213-8
52. Kritz H, Efthimiou Y, Stamatopoulos J, et al. Association of lipoprotein(a), prostaglandin I(2) - synthesis stimulating plasma factor, biological half-life of prostaglandin I(2) and high-density lipoproteins in HIV-1 infection of different stages. Prostaglandins Leukotrienes Essent Fatty Acids 2000;63(5):309-14
53. Singh IP, Chopra AK, Coppenhaver DH, et al. Lipoproteins account for part of the broad non-specific antiviral activity of human serum. Antiviral Res 1999;42(3):211-8
54. Owens BJ, Anantharamaiah GM, Kahlon JB, et al. Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J Clin Invest 1990;86(4):1142-50
55. Fernandez-Miranda C, Pulido F, Carrillo JL, et al. Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers. Clin Chim Acta 1998;274(1):63-70
56. Crook MA, Mir N. Abnormal lipids and the acquired immunodeficiency syndrome: is there a problem and what should we do about it? Int J STD AIDS 1999;10(6):353-6
57. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. New Engl J Med 2003;349:1993-2003
58. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353(9170):2093-9
59. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23(1):35-43
60. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351(9119):1881-3
61. Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001;276(40):37514-9
62. Miserez AR, Muller PY, Spaniol V. Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS 2002;16(12):1587-94
63. Miserez AR, Muller PY, Barella L, et al. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS 2001;15(15):2045-9
64. Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999;84(6):1925-31
65. Christeff N, Melchior JC, De Truchis P, et al. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999;13(16):2251-60
66. Christeff N, Nunez EA, Gougeon ML. Changes in cortisol/DHEA ratio in HIV-infected men are related to immunological and metabolic perturbations leading to malnutrition and lipodystrophy. Ann NY Acad Sci 2000;917:962-70
67. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104(3):257-62
68. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13(10):F63-F70
69. Meyer L, Rabaud C, Ziegler O, et al. Protease inhibitors, diabetes mellitus and blood lipids. Diabetes Metab 1998;24(6):547-9
70. Vigouroux C, Gharakhanian S, Salhi Y, et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999;25(3):225-32
71. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13(13):1659-67
72. Brinkman K, Rosenbaum KR, Wang J. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of anti-retroviral-therapy-related lipodystrophy. Lancet 1999;354(9184):1112-5
73. Chene G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002;34(5):649-57
74. Anon. BHIVA treatment guidelines 2003. http://www bhiva org/guidelines html 2005 July 1
75. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37(5):613-27
76. Currier JS. How to manage metabolic complications of HIV therapy: what to do while we wait for answers. AIDS Reader 2000;10(3):162-9
77. Bergersen BM, Sandvik L, Bruun JN, et al. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004;23(8):625-30
78. Neumann T, Woiwoid T, Neumann A, et al. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: part I. Differences due to the acquisition of HIV-infection. Eur J Med Res 2003;8(6):229-35
79. Neumann T, Woiwod T, Neumann A, et al. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients - part III: age differences. Eur J Med Res 2004;9(5):267-72
80. Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;34(10):1396-405
81. Anon. 'Switch' studies for people with lipodystrophy. Proj Inf Perspect 2000(30):9
82. Geletko SM, ZuWallack AR. Treatment of hyperlipidemia in HIV-infected patients. Am J Health-Syst Pharm 2001;58(7):607-14
83. Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13(7):805-10
84. Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31(5):1266-73
85. Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000;20(9):1066-71
86. Moyle GJ, Lloyd M, Reynolds B, et al. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 2001;15(12):1503-8
87. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002;30(1):26-31
88. Fessel WJ, Follansbee SE, Rego J. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution. AIDS 2002;16(13):1785-9
89. Hsyu PH, Schultz-Smith MD, Lilibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001;45(12):3445-50
90. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32(1):18-29
91. Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, et al. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 2005;21(2):231-44
92. Mikhaildis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005;21(6):959-70
93. Henry K, Melroe H, Huebsch J, et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998;352:1031-2
94. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin and fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19:155-68
95. Balasubramanyam A, Sekhar RV, Jahoor F, et al. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'. Curr Opin Lipidol 2004;15(1):59-67
96. Klein D, Hurley LB, Quesenberry Jr CP, et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30(5):471-7
97. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17(17):2479-86
98. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003;33(4):506-12
99. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000;5(8):329-33
100. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360(9347):1747-8